Gery Tomassoni is a Cardiology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1720 Nicholasville Rd
Suite 601
Lexington, KY 405031404
Telephone
859-277-5887Provider last certified this registry record 4 Dec 2020.
Clinical trials
- Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation
Sponsor: Biosense Webster, Inc.
- MultiPoint Pacing IDE Study
Sponsor: Abbott Medical Devices
- NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
Sponsor: Biosense Webster, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
53 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Vektor Medical Inc.Program year20252 payments$12,120openpaymentsdata.cms.gov ↗
- CARDIVA MEDICAL, INC.Program year20258 payments
- Boston Scientific CorporationProgram year202553 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
68.7%Beta blocker24.2%Metoprolol Tartrate38%Metoprolol Succinate21%Carvedilol15%Sotalol14%Bisoprolol Fumarate6%Atenolol3%Sotalol Af3%Nebivolol Hcl1%Part D<11 patientsAntiarrhythmic21.9%Flecainide Acetate47%Dofetilide31%Amiodarone Hcl13%Propafenone Hcl3%Multaq2%Propafenone Hcl Er2%Mexiletine Hcl2%Part D<11 patients+ 13 more classes in this area
Blood & clotting
29.1%Factor Xa inhibitor24%Eliquis79%Xarelto21%Part D≥192 patientsVitamin K antagonist3.7%Warfarin Sodium100%Part D≥38 patients+ 2 more classes in this area
Metabolism & gastrointestinal
2.2%Potassium supplement0.8%Potassium Chloride67%Klor-Con M2033%Part D<11 patientsProton pump inhibitor0.7%Pantoprazole Sodium100%Part D≥25 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”